LTR Pharma (ASX:LTP) SPONTANĀ® Achieves 470% Faster Absorption in Completed Pivotal Study
By API User
Sydney, Australia – 14 October 2024 – LTR Pharma Limited (ASX: LTP) (“LTR Pharma” or “the Company”) is pleased to announce the successful completion of the pivotal clinical study for SPONTAN®, the Company’s novel intranasal formulation of vardenafil for the treatment of erectile dysfunction (ED). The study’s pharmacokinetic and safety data demonstrate SPONTAN’s rapid onset … Continued